Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||SN-38 + Talazoparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SN-38||SN 38||TOPO Inhibitor (Pan) 3||SN-38 is a metabolite of the topoisomerase inhibitor irinotecan, which causes cell cycle arrest and apoptotic induction, potentially leading to tumor growth inhibition (PMID: 21609311).|
|Talazoparib||Talzenna||BMN673||PARP Inhibitor (Pan) 20||Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Ewing sarcoma||not applicable||SN-38 + Talazoparib||Preclinical - Cell culture||Actionable||In a preclinical study, Ewing sarcoma cells treated with SN-38 combined with Talazoparib (BMN-673) resulted in synergism, demonstrating reduced cell viability in culture (PMID: 26438158).||26438158|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|